This site is intended for US healthcare professionals.
Power to go forward
Power to go forward
The first and only VEGFR TKI proven in mRCC after 2 or more systemic therapies
Pivotal trial.
Primary and long-term PFS.
PFS analysis by subgroup.
Response and OS.
Explore safety and tolerability.
See real-world experience with FOTIVDA.
mRCC=metastatic renal cell carcinoma; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor receptor.